Antibacterial inhalation therapy with thiamphenicol glycinate acetylcysteinate in pulmonology
https://doi.org/10.18093/0869-0189-2018-28-4-483-489
Abstract
Thiamphenicol glycinate acetylcysteinate (TGA) is a combination of thiamphenicol, a broad-spectrum antibiotic, and mucolytic drug N-acetylcysteine. This article is a review of pharmacological, microbiological, and clinical effects of this combined drug. Inhaled TGA could be considered as a worthy alternative for oral mucolytics and oral antibiotics in treatment of upper and lower airway diseases, such as acute and chronic rhinosinusitis, otitis media, tonsillitis, acute bronchitis, and acute exacerbation of chronic bronchitis and chronic obstructive pulmonary disease, in children and adults.
About the Authors
V. A. Kapustina
I.M.Sechenov Federal First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia
Russian Federation
Russian Federation
Candidate of Medicine, Associate Professor, Department No.1 of General Internal Medicine, Medical Faculty
tel.: (499) 245-23-02
ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia
S. I. Ovcharenko
I.M.Sechenov Federal First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia
Russian Federation
Russian Federation
Doctor of Medicine, Professor, Department No.1 of General Internal Medicine, Medical Faculty
tel.: (499) 248-45-23
ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia
References
1. Ageeva L.I., Aleksandrova G.A., Zaychenko N.M. et al. Healthcare in Russia. 2017: Statistical compilation. Moscow: Rosstat; 2017. Available at: http://www.gks.ru/free_doc/doc_2017/zdrav17.pdf (in Russian).
2. MacNee W., Rahman I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160 (5, Pt 2): S58–65. DOI: 10.1164/ajrccm.160.supplement_1.15.
3. Rahman I., MacNee W. Role of oxidants/antioxidants in smoking induced lung diseases. Free Radic. Biol. Med. 1996; 21 (5): 669–681. DOI: 10.1016/0891-5849(96)00155-4.
4. Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343 (4): 269–280. DOI: 10.1056/NEJM200007273430407.
5. Costerton J.W., Geesey G.G., Cheng K.J. How bacteria stick. Sci. Am. 1978; 238 (1): 86–95.
6. El-Azizi M., Rao S., Kanchanapoom T., Khardori N. In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. Ann. Clin. Microbiol. Antimicrob. 2005; (4): 2. DOI: 10.1186/1476-0711-4-2.
7. Sheffner A.L., Medler E.M., Jacobs L.W., Sarett H.P. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am. Rev. Respir. Dis. 1964; 90: 721–729.
8. Iravani J., Melville G.N., Horstmann G. N-Acetylcysteine and mucociliary activity in mammalian airways. Arzneimittelforschung 1978; 28 (2): 250–254.
9. Olivieri D., Marsico S.A., Del Donno M. Improvement of mucociliary transport in smokers by mucolitics. Eur. J. Resp. Dis. Suppl. 1985; (139): 142–145.
10. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. J. Free Radic. Biol. Med. 1989; 6 (6): 593–597. DOI: 10.1016/0891-5849(89)90066-X.
11. Rushworth G.F., Megson I.L. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol. Ther. 2014; (141): 150–159. DOI: 10.1016/j.pharmthera.2013.09.006.
12. Aisanov Z.R., Avdeev S.N., Arkhipov V.V. et al. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Pul’monologiya. 2017; 27 (1): 13–20. DOI: 10.18093/0869-0189-2017-27-1-13-20 (in Russian).
13. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Reports 2018. Available at: https://goldcopd.org/gold-reports/
14. Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2 (3): 187–194. DOI: 10.1016/S2213-2600(13)70286-8.
15. Poole P., Chong J., Cates C.J. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015; (7): CD001287. DOI: 10.1002/14651858.CD001287.pub5.
16. Cazzola M., Calzetta L., Page C. et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 2015; 24 (137): 451–461. DOI: 10.1183/16000617.00002215.
17. Chuchalin A.G., Sinopal'nikov A.I., Kozlov R.S. et al. Russian Respiratory Society Interregional association on clinical microbiology and antimicrobial chemotherapy. Clinical guidelines on diagnosis, treatment and prevention of severe community acquired pneumonia in adults. Pul’monologiya. 2014; (4): 13–48. DOI: 10.18093/0869-0189-2014-0-4-13-48 (in Russian).
18. Lopatin A.S., ed. Acute Rinosinusitis: Clinical Guidelines. Moscow: Russian Society of Rinologists; 2017. Available at: http://rhinology.ru/2017/09/22/ostryj-rinosinusit-klinicheskie-rekomendacii-2017-ror/ (in Russian).
19. Lopatin A.S., ed. Chronic Rinosinusitis: Pathogenesis, Diagnosis and Therapeutic Approaches. Russian Society of Rinologists. Clinical Guidelines. Moscow: Prakticheskaya meditsina; 2014. Available at: http://rhinology.ru/2014/07/14/klinicheskie-rekomendacii-xronicheskij-sinusit/ (in Russian).
20. Albini E., Belluco G., Berton M. et al. In vitro antibacterial activity of thiamphenicol glycinate acetylcysteinate against respiratory pathogens. Arzneimittelforschung. 1999; 49 (6): 533–537. DOI: 10.1055/s-0031-1300456.
21. Rizzato G. Antibiotics for aerosol intake in respiratory infections: pole position for thiamfenicol. L’Internista J. 2001; (9): 120.
22. Lombardi A., Drago L., De Vecchi E. et al. Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae. Arzneimittelforschung. 2001; 51 (3): 264–267. DOI: 10.1055/s-0031-1300034.
23. Drago L., Fassina M.C., Mombelli B. et al. Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. Chemotherapy. 2000; 46 (4): 275–281. DOI: 10.1159/000007299.
24. Raymond J., Boutros N., Bergeret M. [Role of thiamphenicol in the treatment of community-acquired lung infections]. Med. Trop. (Mars). 2004; 64 (1): 33–38 (in French).
25. Melillo G., Chiummariello A., Scala G. [On the use of a new molecular combination of acetylcysteine with thiamphenicol glycinate in bronchopulmonary suppurations]. G. Ital. Chemioter. 1966; 13 (1): 156–160 (in Italian).
26. Bürgi H. Mucolytic and antibiotic effect of a new compound in chronic bronchitis. Chemotherapy. 1975; 21 (3–4): 167–174. DOI: 10.1159/000221857.
27. Mayaud C., Lentschner C., Bouchoucha S., Marsac J. [Thiamphenicol glycinate acetylcysteinate in the treatment of acute respiratory infections with mucostasis]. Eur. J. Respir. Dis. Suppl. 1980; (111): 70–73 (in French).
28. Grassi C., De Benedetto F. Recent clinical evidence of the efficacy and safety of thiamphenicol glycinate acetylcysteinate and thiamphenicol glycinate. J. Chemother. 2002; 14 (3): 279–284. DOI: 10.1179/joc.2002.14.3.279.
29. Vysotiuk L., Hromova A. [Fluimucyl-antibiotic IT: ability of antioxidant therapy for patients with acute attack of infectious chronic obstructive lung disease]. Lik. Sprava. 2006; (1–2): 65–81 (in Ukrainian).
30. Ovcharenko C.I., Morozova N.V. Effective treatment of Fluimucil-antibiotic IT in therapy of exacerbations of COPD. Atmosfera. Pul’monologiya i allergologiya. 2003; (3): 26-28 (in Russian).
31. Ovcharenko S.I., Kapustina V.A., Son E.A. Successful use of the inhaled form of Fluimucil-antibiotic IT in the complex therapy of infectious-inflammatory diseases of the respiratory system. Pharmateka. 2010; 11 (205): 42–45. (In Russian).
32. Ovcharenko S.I., Kapustina V.A., Nersesyan Z.N., Morozova N.V. Modern possibilities of complex nebulizer therapy of exacerbations of chronic obstructive pulmonary disease: clinical observation. Consilium medicum. 2012; (3): 64–66 (in Russian).
33. Ovcharenko S.I., Kapustina V.A. Efficacy and safety of nebulized thiamphenicol glycinate acetylcysteinate in treatment of chronic respiratory diseases. Prakticheskaya meditsina. 2013; 5 (74): 102–105 (in Russian).
34. Belevskiy A.S. Knyazheskaya N.P. Thiamphenicol glycinate acetylcysteinate: some aspects of use in acute and chronic respiratory diseases. Prakticheskaya meditsina. 2017; (3): 122–126 (in Russian).
35. Kolosova N.G., Dronov I.A. Topic inhaled antibacterial therapy of respiratory infections in children. Russkiy meditsinskiy zhurnal. 2017; (5): 319–321 (in Russian).
36. Serra A., Schito G.C., Nicoletti G., Fadda G. A therapeutic approach in the treatment of infections of the upper airways: thiamphenicol glycinate acetylcysteinate in sequential treatment (systemic-inhalatory route). Int. J. Immunopathol. Pharmacol. 2017; 20 (3): 607–617. DOI: 10.1177/039463200702000319.
37. Trushenko N.V., Belevskiy A.S. Etiotropic therapy of acute bronchitis: the discussion goes on. Prakticheskaya meditsina. 2017; (2): 37–47 (in Russian).
38. Varricchio A., Capasso M., Di Gioacchino M., Ciprandi G. Inhaled thiamphenicol and acetylcysteine in children with acute bacterial rhinopharyngitis. Int. J. Immunopathol. Pharmacol. 2008; 21 (3): 625–629. DOI: 10.1177/039463200802100316.
39. Macchi A., Castelnuovo P. Aerosol antibiotic therapy in children with chronic upper airway infections: a potential alternative to surgery. Int. J. Immunopathol. Pharmacol. 2009; 22 (2): 303–310. DOI: 10.1177/039463200902200207.
40. Geppe N.A., Dronov I.A., Kolosova N.G. Efficacy of thiamphenicol glycinate acetylcysteinate in children with acute bronchitis. Russkiy meditsinskiy zhurnal. 2016; (6): 386–390 (in Russian).
Review
For citations:
Kapustina V.A., Ovcharenko S.I. Antibacterial inhalation therapy with thiamphenicol glycinate acetylcysteinate in pulmonology. PULMONOLOGIYA. 2018;28(4):483-489. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-4-483-489
Views:
12707
Email this article 